



Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024

July 25, 2024

WALTHAM, Mass., July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its second quarter 2024 financial results and provide a business update on Thursday, August 1, 2024.

In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, August 1, 2024 to discuss the Company's financial results and provide a business update.

The live audio webcast and accompanying slides may be accessed through the [Events & Presentations page](#) in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:

Conference ID: Syndax2Q24

Domestic Dial-in Number: 800-590-8290

International Dial-in Number: 240-690-8800

Live webcast: <https://www.veracast.com/webcasts/syndax/events/SNDX2Q24.cfm>

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the CSF-1 receptor. For more information, please visit www.syndax.com or follow the Company on [X \(formerly Twitter\)](#) and [LinkedIn](#).

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

 View original content: <https://www.prnewswire.com/news-releases/syndax-to-announce-second-quarter-2024-financial-results-and-host-conference-call-and-webcast-on-august-1-2024-302206073.html>

SOURCE Syndax Pharmaceuticals, Inc.